Literature DB >> 2834466

Western blot analysis of antibody to varicella-zoster virus.

L Dubey1, S P Steinberg, P LaRussa, P Oh, A A Gershon.   

Abstract

We used western blot (WB) to compare the IgG response to varicella-zoster virus (VZV) after chickenpox (CP), zoster, and administration of a live attenuated varicella vaccine (LAVV). After CP, 13 of 14 normal children had antibody to glycoprotein (gp) I (99 and 92 kilodaltons [kDa]), 11 had antibody to gpII (133 kDa), and 10 had antibody to gpIII (119 kDa). Bands at 150 and 35 kDa were also seen in 13 and 11 sera, respectively. Bands to gpI, gpII, and p35 were more intense after zoster than CP. After one dose of LAVV, eight of eight normal children had gpI antibody. In leukemic children, gpI antibody appeared in 18 (56%) after one dose and in 25 (89%) after two doses. Upon household exposure, leukemic vaccinees who developed CP were less likely than those protected to have prior gpIII and p35 antibodies. As seen after zoster, WBs after breakthrough CP showed intense responses to VZV antigens. Thus, WB helps distinguish secondary from primary antibody responses to VZV.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2834466     DOI: 10.1093/infdis/157.5.882

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

Review 1.  A critical appraisal of 'Shingrix', a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus.

Authors:  Tehmina Bharucha; Damien Ming; Judith Breuer
Journal:  Hum Vaccin Immunother       Date:  2017-04-20       Impact factor: 3.452

2.  Acyclovir treatment for varicella does not lower gpI and IE-62 (p170) antibody responses to varicella-zoster virus in normal children.

Authors:  J A Englund; A M Arvin; H H Balfour
Journal:  J Clin Microbiol       Date:  1990-10       Impact factor: 5.948

3.  HSV-1 gB and VZV gp-II crossreactive antibodies in human sera.

Authors:  J E Kühn; K Klaffke; K Munk; R W Braun
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

4.  The glycoprotein products of varicella-zoster virus gene 14 and their defective accumulation in a vaccine strain (Oka).

Authors:  P R Kinchington; P Ling; M Pensiero; B Moss; W T Ruyechan; J Hay
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

Review 5.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

6.  Reactivity of varicella-zoster virus subunit antigens in enzyme-linked immunosorbent assay to sera from varicella, zoster, and herpes simplex virus infections.

Authors:  M Takayama
Journal:  Med Microbiol Immunol       Date:  1994-02       Impact factor: 3.402

7.  Human anti-varicella-zoster virus (VZV) recombinant monoclonal antibody produced after Zostavax immunization recognizes the gH/gL complex and neutralizes VZV infection.

Authors:  Marius Birlea; Gregory P Owens; Emily M Eshleman; Alanna Ritchie; Igor Traktinskiy; Nathan Bos; Scott Seitz; Yevgeniy Azarkh; Ravi Mahalingam; Don Gilden; Randall J Cohrs
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

8.  Neutralizing antibodies induced by recombinant vaccinia virus expressing varicella-zoster virus gpIV.

Authors:  A Vafai; W N Yang
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

9.  Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older.

Authors:  Anthony L Cunningham; Thomas C Heineman; Himal Lal; Olivier Godeaux; Roman Chlibek; Shinn-Jang Hwang; Janet E McElhaney; Timo Vesikari; Charles Andrews; Won Suk Choi; Meral Esen; Hideyuki Ikematsu; Martina Kovac Choma; Karlis Pauksens; Stéphanie Ravault; Bruno Salaun; Tino F Schwarz; Jan Smetana; Carline Vanden Abeele; Peter Van den Steen; Ilse Vastiau; Lily Yin Weckx; Myron J Levin
Journal:  J Infect Dis       Date:  2018-05-05       Impact factor: 5.226

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.